Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer

doi:10.3748/wjg.v18.i10.1104

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3708)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

365

HTML

2875

Figures (1-1)

244

Tables (1-4)

224

Sum=3708

Mar 14, 2012 (publication date) through Jan 9, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104

Table 3 Analysis of survival

End point	Median follow-up duration (range) (mo)	mOS (95% CI) (mo)	mPFS (95% CI) (mo)
Overall	23.87 (6.13-77.83)	14.00 (7.77-20.23)	6.13 (3.94-8.33)
2nd line	22.37 (6.13-56.10)	16.60 (3.22-29.98)	7.23 (6.45-8.02)
3rd line	20.03 (13.87-57.77)	14.07 (6.89-21.25)	7.30 (3.84-10.77)
4th and later-line	51.12 (17.87-77.83)	13.00 (4.48-21.52)	3.87 (2.78-4.95)

mOS: Median overall survival; mPFS: Median progression-free survival; median follow-up duration: From diagnosis to last follow-up date or death date. CI: Confidence interval.

Citation: Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109
URL: https://www.wjgnet.com/1007-9327/full/v18/i10/1104.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i10.1104